

## Special Issue

# Liver Fibrosis: Mechanisms, Targets, Assessment and Treatment

### Message from the Guest Editors

Fibrosis is a double-edged sword. On the one hand, it can be the final state of healed inflammation as scar tissue; on the other hand, it is frequently associated with a reduction in or loss of organ function. Moreover, especially in liver disease, it is a surrogate parameter that indicates the progression of the disease to liver cirrhosis or even hepatocellular carcinoma. This is especially true for non-alcoholic fatty liver disease, a pandemic disorder associated with Western lifestyles and diets. To influence organ fibrosis, it is important to better understand its induction, perpetuation and termination at the molecular level. The induction of liver fibrosis may be metabolic (e.g., alcohol, diet and drugs), infectious (e.g., viruses), autoimmune (e.g., primary biliary cholangitis) or due to monogenetic defects (e.g., increased iron storage). The molecular mechanisms leading to final-stage fibrosis are very different—dependent on its pathogenesis. It is the aim of this Special Issue to provide more insight into these processes.

### Guest Editors

Prof. Dr. Ralf Weiskirchen

Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany

Prof. Dr. Tilman Sauerbruch

Department of Internal Medicine I, University Hospital of Bonn, 53127 Bonn, Germany

### Deadline for manuscript submissions

closed (31 May 2025)



## Livers

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.4  
CiteScore 3.2



[mdpi.com/si/174057](https://mdpi.com/si/174057)

*Livers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[livers@mdpi.com](mailto:livers@mdpi.com)

[mdpi.com/journal/  
livers](https://mdpi.com/journal/livers)





# Livers

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.4  
CiteScore 3.2



[mdpi.com/journal/  
livers](https://mdpi.com/journal/livers)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Hartmut W. Jaeschke

Department of Pharmacology, Toxicology & Therapeutics, University of  
Kansas Medical Center, Kansas City, KS 66160, USA

---

#### Author Benefits

##### High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO,  
and other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is  
provided to authors approximately 27 days after  
submission; acceptance to publication is undertaken in 6.7  
days (median values for papers published in this journal in  
the second half of 2025).

##### Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and  
reviewer names published annually in the journal.